Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

Blueberry consumption is beneficial for hepatic diseases: Study

Conventional drugs used in the treatment of liver diseases inevitably have side effects. An increasing number of natural substances have been studied to explore if they have protective effects on the liver. Blueberries have unique effects on human retinal, brain and tumor cells, but reports about the effects of blueberries on liver diseases are lacking.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

Gary Coleman's death highlights importance of end-of-life decisions

Actor Gary Coleman's death is highlighting the importance of who makes your end-of-life decisions and is drawing attention to the fact that having a "living will" does not always guarantee that your wishes will be carried out, CNN reports.

18 Jun 2010

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the U.S.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.

18 Jun 2010

Baby with heart condition after surgery ‘chilled’ and cured

Four month old baby Finley Burton was taken for a routine visit to his doctor when two holes were detected in his heart. He subsequently underwent an intricate heart operation to close these holes that were making it difficult for his heart to pump out blood. Right after the operation he developed irregular, erratic heart beats that went over 200 beats per minute. This could have killed him but doctors in Britain found a miracle solution for the problem. They lowered his body temperature.

18 Jun 2010

Kennedy Krieger Institute orders for Bruker's ultra-high field MRI CryoProbe

Bruker has received an order for the first ultra-high field MRI CryoProbe in North America to be installed at the F.M. Kirby Research Center for Functional Brain Imaging at the Kennedy Krieger Institute in Baltimore, MD. Supported by an American Recovery and Reinvestment Act (ARRA) award to Dr. Peter van Zijl, Director of the Center, the 500 MHz MRI CryoProbe is part of an ultra-high field preclinical MRI BioSpec® system that includes an 11.7 T UltraShield Refrigerated (USR™) magnet and AVANCE™ III electronics.

17 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

MicroStockProfit.com releases investment report on Somanetics

MicroStockProfit.com announces an investment report featuring Somanetics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Alzheimer's disease may damage brain

Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Micrus Endovascular receives approval to market DeltaPaq, DeltaPlush microcoils for cerebral aneurysms in Japan

Micrus Endovascular Corporation today announced receipt of Shonin approval from the Ministry of Health, Labour and Welfare to market in Japan its novel bare platinum and Cerecyte® DeltaPaq™ filling and DeltaPlush™ finishing microcoils for the treatment of cerebral aneurysms and treatments in the peripheral vasculature.

17 Jun 2010

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

QR Pharma, Inc. (QR) and Massachusetts General Hospital announced today a new collaborative research agreement to work on a treatment for Parkinson's disease (PD).

17 Jun 2010

Brain News and Research

Further Reading

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Blueberry consumption is beneficial for hepatic diseases: Study

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

If you suffer from sleep apnea, consult with your dentist: PDA

Gary Coleman's death highlights importance of end-of-life decisions

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Baby with heart condition after surgery ‘chilled’ and cured

Kennedy Krieger Institute orders for Bruker's ultra-high field MRI CryoProbe

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

MicroStockProfit.com releases investment report on Somanetics

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Alzheimer's disease may damage brain

Research studies may lead to future development of cell transplant therapy for ALS

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Micrus Endovascular receives approval to market DeltaPaq, DeltaPlush microcoils for cerebral aneurysms in Japan

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News